Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-term ATO + ATRA for acute promyelocytic leukemia
ChiCTR-OIC-16007972Phase 2Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of arsenic trioxide and tretinoin in Acute promyelocytic leukaemia (APL), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: 3-year leukemia-free survival rate. Started Apr 2016; status: recruiting.
02
Drugs
arsenic trioxidetretinoin
03
Conditions
Acute promyelocytic leukaemia (APL)
Beyond the preview
Go deeper on ChiCTR-OIC-16007972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OIC-16007972.